ANI Pharmaceuticals (NASDAQ:ANIP) Announces Earnings Results, Beats Expectations By $0.77 EPS

ANI Pharmaceuticals (NASDAQ:ANIP) released its quarterly earnings results on Friday. The specialty pharmaceutical company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.77, FiscalAI reports. The business had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.97% and a net margin of 8.87%.ANI Pharmaceuticals’s quarterly revenue was up 20.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.70 EPS. ANI Pharmaceuticals updated its FY 2026 guidance to 9.190-9.690 EPS.

Here are the key takeaways from ANI Pharmaceuticals’ conference call:

• ANI raised its 2026 guidance, now targeting $1.08B–$1.14B in revenue, $285M–$300M adjusted EBITDA and $9.19–$9.69 adjusted EPS, driven by rare disease strength.
• Cortrophin Gel revenue grew 42% YoY to $75.1M in Q1, April saw the highest new patient starts since launch, and a 64‑rep commercial expansion into primary care and podiatry is being deployed to accelerate H2/2026 and 2027 growth.
• ANI recognized a $15M upfront fee from an out‑license to Harmony Biosciences, expects an additional $10M in near‑term development milestones (Q2–Q3) and low‑single‑digit royalties on pitolisant (WAKIX), adding immediate cash and future royalty upside.
• Generics continue to fund growth with Q1 generics revenue of $105.4M (up 7%), six new launches YTD and a steady 10–15 launch cadence, while management authorized a new $100M share repurchase program as part of disciplined capital allocation.
• Q1 results were impacted by insurance reverification delays and weather‑related office closures that temporarily depressed early‑quarter Cortrophin volumes and contributed to a lower non‑GAAP gross margin (60.8%), and ILUVIEN still faces ongoing Medicare access challenges.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $81.86 on Friday. The company has a current ratio of 2.71, a quick ratio of 2.19 and a debt-to-equity ratio of 1.11. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of 24.36 and a beta of 0.46. The stock has a 50 day moving average of $76.82 and a 200 day moving average of $81.01. ANI Pharmaceuticals has a 12 month low of $56.71 and a 12 month high of $99.50.

Insider Activity at ANI Pharmaceuticals

In related news, insider Christopher Mutz sold 3,162 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $71.64, for a total transaction of $226,525.68. Following the completion of the sale, the insider directly owned 91,309 shares of the company’s stock, valued at approximately $6,541,376.76. This trade represents a 3.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Stephen P. Carey sold 7,312 shares of the firm’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $75.50, for a total value of $552,056.00. Following the completion of the sale, the chief financial officer directly owned 185,543 shares of the company’s stock, valued at $14,008,496.50. This represents a 3.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 27,860 shares of company stock valued at $2,111,581 in the last ninety days. Insiders own 8.10% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. Maryland State Retirement & Pension System increased its position in ANI Pharmaceuticals by 5.4% in the fourth quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock worth $206,000 after buying an additional 134 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its position in ANI Pharmaceuticals by 1.0% in the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock worth $1,267,000 after buying an additional 198 shares during the last quarter. Federation des caisses Desjardins du Quebec increased its position in ANI Pharmaceuticals by 0.6% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 39,391 shares of the specialty pharmaceutical company’s stock worth $3,110,000 after buying an additional 221 shares during the last quarter. Amundi increased its position in ANI Pharmaceuticals by 1.2% in the third quarter. Amundi now owns 23,918 shares of the specialty pharmaceutical company’s stock worth $2,202,000 after buying an additional 285 shares during the last quarter. Finally, Alliancebernstein L.P. increased its position in ANI Pharmaceuticals by 1.5% in the third quarter. Alliancebernstein L.P. now owns 20,310 shares of the specialty pharmaceutical company’s stock worth $1,860,000 after buying an additional 300 shares during the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI Pharmaceuticals beat Wall Street expectations on both earnings and revenue, reporting $2.05 EPS versus $1.28 expected and revenue of $237.46 million versus $207.63 million expected. The company also said quarterly revenue rose 20.5% year over year, signaling solid underlying growth. Article Title
• Positive Sentiment: The company raised its FY 2026 EPS guidance to $9.19-$9.69, above the consensus estimate of $8.79, which suggests management sees stronger profitability ahead. Article Title
• Neutral Sentiment: Investors are also parsing the earnings call transcript and presentation for details on the company’s growth drivers and updated strategy, but the main stock catalyst today is the beat-and-raise quarter. Article Title
• Neutral Sentiment: ANI also issued revenue guidance around $1.1 billion for FY 2026, roughly in line with expectations, so the revenue outlook appears stable rather than a fresh upside surprise. Article Title

Analysts Set New Price Targets

ANIP has been the subject of a number of analyst reports. Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 15th. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Finally, Guggenheim increased their price target on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, January 16th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.